bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Down 54.1% in February

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a large decrease in short interest in the month of February. As of February 28th, there was short interest totalling 115,500 shares, a decrease of 54.1% from the February 13th total of 251,900 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average trading volume of 189,000 shares, the short-interest ratio is currently 0.6 days.

bioAffinity Technologies Price Performance

bioAffinity Technologies stock traded up $0.01 during midday trading on Friday, reaching $0.37. 70,954 shares of the stock were exchanged, compared to its average volume of 148,679. The company’s fifty day moving average is $0.68 and its 200-day moving average is $1.16. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.01 and a current ratio of 1.02. The firm has a market cap of $5.72 million, a PE ratio of -0.45 and a beta of 3.13. bioAffinity Technologies has a 52 week low of $0.26 and a 52 week high of $3.16.

Institutional Trading of bioAffinity Technologies

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC increased its position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 46,304 shares of the company’s stock after acquiring an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned approximately 0.30% of bioAffinity Technologies worth $42,000 as of its most recent filing with the Securities and Exchange Commission. 1.64% of the stock is owned by institutional investors and hedge funds.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.